Betty Y. Chang

Betty Y. Chang, PhD, is the Head of Research, leading efforts for discovering new molecules for the growing pipeline.

Prior to Summit, Dr. Chang was Senior Vice President of Translational Research and Early Development, part of the executive team, of Molecular Templates, an immunotoxin company where she was responsible for pharmacology, toxicology, and clinical PK/PD functions. From 2018-2019, she was Chief Operating Officer & Executive Vice President of Product Development at Angarus Therapeutics, an early-stage start-up. From 2009-2018, she was at Pharmacyclics (acquired by AbbVie in 2015) where she was ultimately the Head & Vice President of Research. In that function, she built and led the strategy and operations of a team responsible for drug discovery, pharmacology, translational medicine, and early development activities for IMBRUVICA® (ibrutinib). Dr. Chang started her career at Cell Genesys, a gene / cell therapy company in 1999, and then was an Associate Director at Rigel and Alder Biopharmaceuticals with increasing responsibilities in research and development.

Dr. Chang has published over 100 research manuscripts, conference abstracts, and patent publications. Dr. Chang received her Ph.D. degree in Biochemistry and Molecular Biology from the University of California, Davis, and completed her postdoctoral fellowship in cancer biology at Stanford School of Medicine.